Full-Time
Posted on 5/20/2025
Develops and commercializes biopharmaceuticals for various diseases
No salary listed
Junior, Mid
Cork, Ireland
Gilead Sciences is a biopharmaceutical company that develops and sells medicines for various serious health conditions, including HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular issues. The company focuses on extensive research and development to create new therapies, which are then approved by regulatory authorities before being marketed to healthcare providers and pharmacies. Gilead stands out from its competitors by investing heavily in R&D and forming strategic partnerships, such as with SAP Ariba, to improve its supply chain and product offerings. The company's goal is to enhance health equity and access to care globally, working with communities to ensure that its medicines reach those in need.
Company Size
10,001+
Company Stage
IPO
Headquarters
Foster City, California
Founded
1987
Help us improve and share your feedback! Did you find this helpful?
Paid family time off and paid parental time off
Generous 401(k) contribution matching
Comprehensive medical plans that cover both physical and mental healthcare
Global Wellbeing Reimbursement
Time Off
Global Volunteer Day
Giving Together Program
Employee Support Programs
Flexible Work Options
GAINESVILLE, Fla., June 1, 2025 /PRNewswire/ -- The Academy of Oncology Nurse & Patient Navigators (AONN+) is proud to announce the launch of a groundbreaking grant program in partnership with Gilead Sciences aimed at advancing the field of oncology navigation and enhancing patient outcomes within the healthcare setting. This initiative is designed to support the creation, enhancement, and expansion of innovative tools that optimize efficiency and elevate the critical role of oncology navigators.Following the AONN+ call for grant submissions in April, healthcare leaders across the country responded with creative applications, software solution ideas and healthcare system improvements. AONN+ looks to announce the recipients of the award, valued up to $500,000, in June with project work to begin in the July time frame. The AONN+ grant application process and implementation support for awardees also included help from Amplity, AONN+'s association management partner and strategic collaborator."Through this funding mechanism, AONN+ and Gilead are committed to addressing persistent challenges in cancer care by empowering navigators to play a pivotal role in improving patient access to navigation services, removing barriers to cancer care, and supporting treatment adherence," says Candice Roth, MSN, RN, CENP, Executive Director, AONN+. "Navigator utilization continues to present significant opportunities for optimizing patient outcomes, and this program seeks to provide impactful solutions that directly tie proposed tools to measurable improvements in patient care.""As part of Gilead's Community Cancer Collective, we are proud to partner with AONN+ on this exciting initiative in support of the oncology community," said Darren Tayama, M.D., Vice President, US Medical Affairs, Oncology. "Together, AONN+ and Gilead are advancing the future of cancer care through innovative solutions in oncology navigation."About the Academy of Oncology Nurse & Patient Navigators , Inc
Newsletter Signup - Under Article / In Page"*" indicates required fields Interleukins — a group of signaling proteins that help immune cells communicate — have long been recognized as powerful tools in modulating immune responses. Over the years, companies have explored interleukin as treatments for cancer, autoimmune conditions, and inflammatory diseases. But while some interleukin-based drugs have reached the market, many early attempts were held back by toxicity and a lack of precision.Today, that’s starting to change. Advances in protein engineering, mRNA technology, and cell-targeted delivery have opened up new ways to harness interleukins more safely and effectively. Big pharma is already active in this space, but a growing number of smaller biotech companies are helping to push the field forward.In this list, we take a look at some of the most interesting biotech companies and emerging players developing interleukin therapeutics. Ankyra Therapeutics Headquarters: Cambridge, MassachusettsFounded: 2019Recent News: Presented preliminary phase 1 clinical data for ANK-101 at the AACR Annual MeetingAnkyra Therapeutics is a biotech developing anchored immunotherapies aimed at enhancing the therapeutic window of cytokine-based treatments. The company’s lead candidate, ANK-101 (tolododekin alfa), is an interleukin-12 (IL-12) cytokine anchored to aluminum hydroxide, designed for localized delivery to tumors.ANK-101 employs Ankyra’s proprietary Anchored Immunotherapy Platform, which involves fusing IL-12 with an alum-binding peptide, allowing the complex to bind to aluminum hydroxide (Alhydrogel)
This time it's Gilead coming to the table with a fresh $11 billion in hand to spend across its manufacturing and research centers in the U.S.
Gilead to invest $32 billion in U.S. manufacturing and R&D through 2030 and create more than 3,000 direct and indirect jobs by 2028
On April 29, the Department of Justice (DOJ) announced that California-based pharmaceutical giant Gilead Sciences agreed to pay $202 million to settle charges of violating the False Claims Act and Anti-Kickback Statute.